pubmed-article:1822788 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C0442025 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C0017919 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C0011900 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C0877853 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C0205296 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
pubmed-article:1822788 | lifeskim:mentions | umls-concept:C2346714 | lld:lifeskim |
pubmed-article:1822788 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:1822788 | pubmed:dateCreated | 1992-9-10 | lld:pubmed |
pubmed-article:1822788 | pubmed:abstractText | Natural abundance 13C NMR (nuclear magnetic resonance) spectroscopy was used to distinguish patients suffering from muscle glycogenosis type V (McArdle's disease) from normal subjects by measuring their muscle glycogen content at rest. Proton-decoupled 13C spectra were obtained in 10-15 min from calf muscles at rest. The ratio of the glycogen/creatine signal areas was 12.9 +/- 1.7 in four McArdle's disease patients and 2.0 +/- 0.7 in seven normal subjects. This technique thus allows the non-invasive diagnosis of muscle glycogenosis. | lld:pubmed |
pubmed-article:1822788 | pubmed:language | eng | lld:pubmed |
pubmed-article:1822788 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1822788 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1822788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1822788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1822788 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1822788 | pubmed:issn | 0960-8966 | lld:pubmed |
pubmed-article:1822788 | pubmed:author | pubmed-author:BlochGG | lld:pubmed |
pubmed-article:1822788 | pubmed:author | pubmed-author:FardeauMM | lld:pubmed |
pubmed-article:1822788 | pubmed:author | pubmed-author:SyrotaAA | lld:pubmed |
pubmed-article:1822788 | pubmed:author | pubmed-author:DuboeFF | lld:pubmed |
pubmed-article:1822788 | pubmed:author | pubmed-author:JehensonPP | lld:pubmed |
pubmed-article:1822788 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1822788 | pubmed:volume | 1 | lld:pubmed |
pubmed-article:1822788 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1822788 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1822788 | pubmed:pagination | 99-101 | lld:pubmed |
pubmed-article:1822788 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:meshHeading | pubmed-meshheading:1822788-... | lld:pubmed |
pubmed-article:1822788 | pubmed:year | 1991 | lld:pubmed |
pubmed-article:1822788 | pubmed:articleTitle | Diagnosis of muscular glycogenosis by in vivo natural abundance 13C NMR spectroscopy. | lld:pubmed |
pubmed-article:1822788 | pubmed:affiliation | Service Hospitalier Frederic Joliot, CEA, Orsay, France. | lld:pubmed |
pubmed-article:1822788 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1822788 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1822788 | lld:pubmed |